Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0997 • ACR Convergence 2023
Impact of Depression on Healthcare Utilization in Members with Underlying Rheumatoid Arthritis, Psoriatic Arthritis and Systemic Lupus Erythematosus
W. Cliff Rutter, Jean Park, Elisea Avalos-Reyes, Chen Liu, Will Cavers, Dorothea Verbrugge and Kjel Johnson, CVS Health, Woonsocket, RI
Background/Purpose: Patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and systemic lupus erythematosus (SLE) have higher rates of psychiatric comorbidities, particularly depression and anxiety. Comorbid…
Abstract Number: 1081 • ACR Convergence 2023
Clinical Consequences of Infliximab Immunogenicity and the Impact of Proactive Therapeutic Drug Monitoring: Secondary Analyses of a Randomised Clinical Trial
Marthe Brun¹, Kristin Hammersbøen Bjørlykke², Johanna E. Gehin³, David John Warren³, Rolf A. Klaasen³, Joseph Sexton¹, Øystein Sandanger⁴, Tore Kvien¹, Cato Mørk⁵, Jørgen Jahnsen², Nils Bolstad³, Kristin Kaasen Jørgensen², Espen Haavardsholm¹, Guro Goll¹ and Silje Watterdal Syversen¹, ¹Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, ²Department of Gastroenterology, Akershus University Hospital, Oslo, Norway, ³Dept. of Medical Biochemistry, Oslo University Hospital, Oslo, Norway, ⁴Section of Dermatology, Oslo University Hospital, Oslo, Norway, ⁵Akershus Dermatology Center, Lørenskog, Norway
Background/Purpose: Formation of anti-drug antibodies (ADAb) to biological drugs is a clinical problem. Proactive therapeutic drug monitoring (TDM) allows for timely detection of ADAb and…
Abstract Number: 1274 • ACR Convergence 2023
Rheumatoid Arthritis Patients, Achieving Low Disease Activity State or Remission, Still Demonstrate Significant Hand Disability, as Assessed by Functional Dexterity Test: A Disconnection Between CDAI and Functional Hand Assessment
Aniela Shouval¹, Amihai Levkovitch², Itzhak Rosner³, shiri keret⁴, Irina Rokhyan², Boris Tchalabian², Esther Hof⁵ and Gleb Slobodin⁶, ¹Bnai Zion Medical Center, Haifa, Israel, ²Department of Rehabilitation, Bnai Zion Medical Center, Haifa, Israel, ³Bnai Zion Medical Center/Technion, Haifa, Israel, ⁴Bnai Zion, Atlit, Israel, ⁵Occupational Therapy Unit, Bnai zion Medical Center, Haifa, Israel, ⁶Rheumatology Unit, Bnai Zion Medical Center, Haifa, Israel
Background/Purpose: Direct functionality of the hand is not commonly assessed in daily practice or clinical trials in patients with rheumatoid arthritis (RA). Functional dexterity test…
Abstract Number: 1290 • ACR Convergence 2023
Development of a Genetic Risk Score for Pain in Rheumatoid Arthritis
Katie McMenamin¹, Kristin Wipfler², Austin Wheeler³, Grant Cannon⁴, K Wysham⁵, Brian Sauer⁶, Bryant England³, Kaleb Michaud³, Ted R Mikuls⁷ and Joshua Baker⁸, ¹Boston University, Boston, MA, ²FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ³University of Nebraska Medical Center, Omaha, NE, ⁴University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁵VA Puget Sound/University of Washington, Seattle, WA, ⁶Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁷Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE, ⁸University of Pennsylvania, Philadelphia, PA
Background/Purpose: Pain in rheumatoid arthritis (RA) is multifactorial and involves processes beyond inflammation such as peripheral and central pain processing. Several genes have been associated…
Abstract Number: 1306 • ACR Convergence 2023
Statin Use Attenuates the Impact of Systemic Inflammation on Ischemic Cardiovascular Risk in Patients with Rheumatoid Arthritis
George Karpouzas¹, Sarah Ormseth², Piet Van Riel³, Elena Myasoedova⁴, Miguel A Gonzalez-Gay⁵, Alfonso Corrales⁶, Solbritt Rantapaa-Dahlqvist⁷, Petros Sfikakis⁸, Patrick Dessein⁹, Linda Tsang⁹, Carol Hitchon¹⁰, Hani El Gabalawi¹¹, Virginia Pascual Ramos¹², Irazú Contreras Yañez¹³, Iris Colunga¹⁴, Dionicio A. Galarza-Delgado¹⁴, José Ramón Azpiri-López¹⁴, Silvia Rolefstad¹⁵, Anne Grete Semb¹⁶, Durga P Misra¹⁷, George Kitas¹⁸ and Ellen-Margrethe Hauge¹⁹, ¹Harbor-UCLA Medical Center, Torrance, CA, ²The Lundquist Institute, Torrance, CA, ³Radboud University Medical Center, Drunen, Netherlands, ⁴Mayo Clinic, Rochester, MN, ⁵IDIVAL and School of Medicine, UC, Santander; Department of Rheumatology, IIS-Fundación Jiménez Díaz, Madrid, Santander, Spain, ⁶Rheumatology Department, Immunopathology Group, Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander, Spain, ⁷Umeå University, Umeå, Umea, Sweden, ⁸National Kapodistrian University of Athens Medical School, Athens, Greece, ⁹University of Witwatersrand, Johannesburg, South Africa, ¹⁰University of Manitoba, Manitoba, MB, Canada, ¹¹University of Manitoba, Winnipeg, MB, Canada, ¹²Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ¹³Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ¹⁴Hospital Universitario UANL, Monterrey, Mexico, ¹⁵Diakonhjemmet Hospital, Oslo, Norway,, Oslo, Norway, ¹⁶Diakonhjemmet Hospital, Oslo, Norway, ¹⁷Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, ¹⁸The Dudley Group NHS Foundation Trust, Birmingham, United Kingdom, ¹⁹Aarhus University Hospital, Aarhus, Denmark
Background/Purpose: Baseline and cumulative inflammation have both been associated with increased cardiovascular event (CVE) risk in patients with rheumatoid arthritis (RA). Statin therapy reduced systemic…
Abstract Number: 1323 • ACR Convergence 2023
Distinct Treatment Responses in Patients with Rheumatoid Arthritis Receiving Filgotinib 200 Mg over 12 Months: A Post Hoc Analysis of FINCH 1
Peter C. Taylor¹, Yoshiya Tanaka², Emily Aiello³, Thomas P.A. Debray⁴, Chris Watson⁵, Kristina Harris⁶ and Gerd Burmester⁷, ¹Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ²University of Occupational and Environmental Health, Kitakyushu, Japan, ³Real-world Analytics, Cytel, Toronto, ON, Canada, ⁴Biostatistics, Galapagos NV, Mechelen, Belgium, ⁵Medical Affairs, Galapagos Biotech Ltd., Cambridge, United Kingdom, ⁶Medical Safety, Galapagos NV, Mechelen, Belgium, ⁷Charité – Universitätsmedizin Berlin, Department of Rheumatology and Clinical Immunology, Berlin, Germany
Background/Purpose: FINCH 1 (NCT02889796) was a Phase 3 randomized controlled trial evaluating filgotinib (FIL) in patients with rheumatoid arthritis and an inadequate response to methotrexate…
Abstract Number: 1339 • ACR Convergence 2023
Neutrophil Activation and Formation of Neutrophil Extracellular Traps Are Associated with Response to Abatacept in Patients with Moderate to Severe Rheumatoid Arthritis
Ting Wang¹, Natalia V. Giltiay², Christian Lood² and Bobby Kwanghoon Han², ¹University of Washington, Seattle, WA, ²Division of Rheumatology, University of Washington, Seattle, WA
Background/Purpose: Neutrophil activation and formation of neutrophil extracellular traps (NETs) have been implicated in the pathogenesis of rheumatoid arthritis (RA). Calprotectin, a neutrophil activation marker,…
Abstract Number: 1628 • ACR Convergence 2023
The Impact of Cardiovascular and Cerebrovascular Disease on the Risk of Dementia in Rheumatoid Arthritis. a Mediation Analysis
Edward Lovering¹, Chanakya Kodishala², Rakesh Kumar¹, Cynthia Crowson¹, Ryan Lennon¹, John Davis¹ and Elena Myasoedova¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic Rochester Minnesota, Rochester, MN
Background/Purpose: Alzheimer's disease and related dementias have an immense disease burden, with predicted continuous increase in incidence and prevalence. Systemic inflammation plays a major role…
Abstract Number: 1721 • ACR Convergence 2023
The Therapeutic Effects of Gingival Mesenchymal Stem Cells and Their Exosomes in a Chimeric Model of Rheumatoid Arthritis
shane Bruckner¹, Braden Zeno², Vittoria Capria¹, William Willis³, Latha Prabha Ganesan¹ and wael Jarjour¹, ¹Ohio State University, Columbus, OH, ²Ohio State University, Upper Arlington, OH, ³Ohio State University, Reynoldsburg, OH
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease that leads to progressive joint destruction involving multiple joints. There is a large body of…
Abstract Number: 1740 • ACR Convergence 2023
Exploring Disease-Associated DNA Methylome Alterations in Rheumatoid Arthritis: Potential Diagnostic and Prognostic Biomarkers
Arkaitz Mucientes¹, Martín-Núñez Gracia María², José Lisbona-Montañez³, Patricia Ruiz-Limon⁴, Rocío Redondo-Rodríguez⁵, SARA MANRIQUE⁶, Inmaculada Ureña⁵, Laura Cano-García⁵, Isabel Moreno-Indias¹, Natalia Mena Vazquez⁷ and Antonio Fernandez-Nebro⁸, ¹IBIMA Plataforma BIONAND, Málaga, Spain, ²Universidad de Málaga, Departamento de Medicina y Dermatología, Málaga, Spain, ³Universidad de Málaga, Departamento de Medicina y Dermatología, Moclinejo, Spain, ⁴IBIMA Plataforma BIONAND, Cordoba, Spain, ⁵Division of Rheumatology, Hospital Regional Universitario Carlos Haya, Málaga, Spain, ⁶Division of Rheumatology, Hospital Regional Universitario Carlos Haya, Malaga, Spain, ⁷IBIMA, Málaga, Spain, ⁸Hospital Regional Universitario de Málaga, Malaga, Spain
Background/Purpose: The etiology of rheumatoid arthritis (RA) is not fully understood. It is accepted that RA results from the interplay of genetic and environmental factors.…
Abstract Number: 1756 • ACR Convergence 2023
Circulating CD4+CD25+CD127-FoxP3+CD39+ T Cells Predict the Response to Methotrexate Across Basal Disease Activity Strata in Early Rheumatoid Arthritis
Maria-Eugenia Miranda-Carus¹, Beatriz Nieto-Carvalhal¹, Alejandro Villalba², Laura Nuño¹, Marta Benito-Miguel³, Marta Novella-Navarro⁴, Irene Monjo⁵, Diana Peiteado¹, Sara García-Carazo¹ and Alejandro Balsa⁴, ¹Hospital Universitario La Paz - IdiPAZ, Madrid, Spain, ²Rheumatology Department, La Paz University Hospital, Madrid, Spain, ³Universidad Nebrija, Physiology, Madrid, Spain, ⁴Hospital Universitario La Paz, Madrid, Spain, ⁵University Hospital La Paz, Madrid, Spain
Background/Purpose: A subset of human FoxP3+ regulatory T (Treg) cells expresses CD39 (Treg39+) and hydrolyses proinflammatory adenine nucleotides released at inflammatory foci, rendering the antiinflamatory…
Abstract Number: 1772 • ACR Convergence 2023
Rheumatoid Arthritis-Specific Rheumatoid Factors Develop in Some COVID-19 Patients
Adam Titi¹, Ryan Adyniec², Nat Murren¹ and Miriam Shelef¹, ¹University of Wisconsin, Madison, WI, ²University of Wisconsin-Madison, Madison, WI
Background/Purpose: Rheumatoid factors (RFs), antibodies canonically known to bind two conformational epitopes of IgG Fc, are a hallmark of rheumatoid arthritis (RA) but also can…
Abstract Number: 1887 • ACR Convergence 2023
Total-body PET Quantitative Biomarkers Reveal Key Differences in Enthesitis Between Rheumatoid and Psoriatic Arthritis Patients
Dario Mazza¹, Siba Raychaudhuri², Yasser Abdelhafez¹ and Abhijit Chaudhari³, ¹University of California Davis, Sacramento, CA, ²UC Davis, School of Medicine/ VA Medical Center, Sacramento, Davis, CA, ³UC Davis School of Medicine, Sacramento, CA
Background/Purpose: To evaluate the ability of total-body PET (TB-PET) biomarkers to quantify enthesitis in Psoriatic (PsA) and Rheumatoid Arthritis (RA). We hypothesize that objective characterization…
Abstract Number: 2034 • ACR Convergence 2023
Assessment of the Immediate and Short-term Impact of an Information Course on Patients’ Knowledge About Rheumatoid Arthritis: Evaluation Using a Self-prepared and Validated Assessment Questionnaire
Ranjan Gupta¹, Rudra Prosad Goswami², Manshi Yadav¹, Sandhya Saini¹, Anju Mohan¹ and Vanamail Perumal¹, ¹All India Institute of Medical Sciences, New Delhi, India, ²Department of Rheumatology, All India Institute of Medical Sciences, New Delhi, India
Background/Purpose: Long-term outcomes in rheumatic diseases can be improved by improving patients' knowledge, beliefs and perception about their disease which can help them in coping…
Abstract Number: 2110 • ACR Convergence 2023
Rheumatoid Arthritis and Changes in Pulmonary Function Measures on Spirometry in a Prospective Longitudinal Cohort of Smokers
Keigo Hayashi¹, Gregory McDermott¹, Pierre-Antoine Juge², Matthew Moll¹, Michael Cho¹, Tracy J. Doyle¹, Gregory Kinney³, Danielle Sansone-Poe³, Kendra Young³, Paul Dellaripa⁴, Zachary Wallace⁵, Elizabeth Regan⁶, Gary Hunninghake¹, Edwin Silverman¹, Samuel Ash¹, Raul San Jose Estepar¹, George Washko¹ and Jeffrey Sparks⁷, ¹Brigham and Women's Hospital, Boston, MA, ²Division of Rheumatology, Inflammation, and Immunity Brigham & Women's Hospital, Boston, MA, ³University of Colorado Denver, Denver, CO, ⁴Brigham and Women's Hospital, Boston, MA, ⁵Massachusetts General Hospital, Newton, MA, ⁶National Jewish Health, Denver, CO, ⁷Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Rheumatoid arthritis (RA) has known extra-articular manifestations that can result in restrictive and obstructive patterns on pulmonary function measures, especially in smokers. However, investigations…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].